First Targeted Bladder Cancer Treatment Shows Promising Phase I Results
Posted:
In a potential win for targeted therapy in bladder cancer, Johnson & Johnson announced results from a Phase I study of erdafitinib (Erda-iDRS) in patients with the intermediate-risk non-muscle-invasive form of the disease.
Obsessive-compulsive disorder (OCD) remains one of psychiatry’s most disabling conditions, affecting about 1-2% of the population. People with OCD have an 82% increase in all cause mortality compared with unnafected matched people from the general population, with suicide being a major contributor.…
The French pharma company Servier said Friday that it would buy Day One Biopharmaceuticals, the maker of a drug for childhood brain tumors, in a deal worth roughly $2.5 billion.
Read more here.
Attendees
Sponsors and Exhibitors
Contact us